This protocol models retinal ischemia-reperfusion injury in a mouse eye by inducing retinal ischemia via anterior chamber cannulation and intraocular pressure elevation, followed by intraocular pressure normalization to initiate the reperfusion.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
This protocol models retinal ischemia-reperfusion injury in a mouse eye by inducing retinal ischemia via anterior chamber cannulation and intraocular pressure elevation, followed by intraocular pressure normalization to initiate the reperfusion.
Ischemia-reperfusion injuries are known to cause a range of retinal pathologies, including diabetic retinopathy, glaucoma, retinal vascular occlusions, and other vaso-occlusive conditions. This manuscript presents a method for inducing ischemia-reperfusion injury in a mouse model. The method utilized anterior chamber cannulation attached to a saline reservoir, generating hydrostatic pressure to raise the intraocular pressure to 90-100 mmHg. This method effectively caused constriction of retinal capillaries to induce retinal ischemia. At the end of the ischemic period (60 min), the intraocular pressure was normalized (≤20 mmHg) before removing the cannula from the anterior chamber to initiate reperfusion. Days after the ischemia/reperfusion procedure, the eyes were collected and sectioned for histological staining. The histopathology of the retinal sections was scored by evaluating eight parameters of retinal injury: folds, hemorrhage, deformation, cell loss in the ganglion cell, inner nuclear, outer nuclear, and photoreceptor layers, and damage to retinal pigment epithelial cells. This method provided a reproducible model to study the mechanisms and pathology of retinal ischemia/reperfusion injury. In addition, this model can facilitate the discovery of potential therapeutic targets to treat retinal ischemia/reperfusion injury, advancing the study of retinal pathologies and improving patient outcomes.
Ischemia/reperfusion injuries manifest in various retinal pathologies, encompassing diabetic retinopathy, glaucoma, retinal vascular occlusions, and related vaso-occlusive conditions. Given the retina's high oxygen demand, it is particularly susceptible to ischemia/reperfusion injury, a phenomenon implicated in the pathogenesis of diseases like diabetic retinopathy. This form of injury results in the demise of retinal ganglion cells (RGCs), morphological degeneration of the retina, compromised retinal function, and eventual vision impairment1. Modeling the ischemia/reperfusion is appropriate for studies on mechanisms and treatment responses in ....
Access restricted. Please log in or start a trial to view this content.
All procedures were performed according to an animal use protocol approved by the Boston University Institutional Animal Care and Use Committee according to the NIH Guide for the Care and Use of Laboratory Animals and complies with the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research.
1. Experimental animals
2. Preparing the required solution and infusion line
Access restricted. Please log in or start a trial to view this content.
To assess the pathology of the retinas after the ischemia/reperfusion, eyes were collected from one group of mice 2 days after the procedure and from another group of mice 7 days after the procedure. The enucleated eyes were fixed in 4% paraformaldehyde, embedded in paraffin, and sliced into 5 µm sections. The sections were stained with hematoxylin and eosin (H&E) and imaged for histological examination (Figure 1). The stained histological images showed damage and loss of cells in the re.......
Access restricted. Please log in or start a trial to view this content.
The ischemia/reperfusion model provides a reproducible method for studying the mechanisms and pathology of retinal ischemia/reperfusion injury. This model has usefulness in studying the pathology of retinal ischemia/reperfusion injury, and for identifying therapeutic targets. Several critical steps in the protocol may pose challenges and require technical skills to complete successfully. One is the actual cannulation, which can take multiple attempts to master and has a risk of damage to other structures in the eye. Addi.......
Access restricted. Please log in or start a trial to view this content.
The authors have no disclosures.
Thank David Yee for his technical assistance. The work was supported in part by the Massachusetts Lions Eye Research Foundation and the Boston University Chobanian & Avedisian School of Medicine Wing Tat Lee Award.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 0.5% Proparacaine | Sandoz | 61314-016-01 | |
| 1% tropicamide | Sumerset Therapeutics | 700069-016-01 | |
| 30 G needle | Becton Dickinson | 305106 | |
| 4% paraformaldehyde | Electron Microscopy Sciences | 15700 | |
| Bluing reagent | Fisher Scientific | 22-050-114 | |
| C57BL/6J mice | Jackson Laboratories | 664 | |
| Dissecting Microscope | Olympus | SZ61 | |
| Eosin stain | Electron Microscopy Sciences | 26051-11 | |
| Hematoxylin stain | Electron Microscopy Sciences (Gill's #2) | 26030-20 | |
| Imager | Olympus | Q-Color 5 | |
| Infusion line (included in the in vivo perfusion system) | Braintree Scientific | IV4140 | |
| Ketamine | Covetrus | 10004027 | Zoetis NDC# 00856440301 |
| Microscope | Olympus | CX-33 | |
| Microtome | Microm | HM335S | |
| Ophthalmic antibacterial ointment | Henry Schein | 1410468 | Baush & Lomb NDC# 2420879535 |
| Permount Mounting Media | Fisher Scientific | SP15-100 | |
| Prism | GraphPad | 10.3.1 for macOS | data collection, statistical anlaysis, graphs |
| Saline Solution | KD Medical Inc | 50-103-1363 | |
| Stopcock (included in the in vivo perfusion system) | Braintree Scientific | IV4140 | |
| Tonometer | iCare | TA01i | |
| Xylazine | Covetrus | 1XYL006 | Covetrus NDC# 11695402401 |
Access restricted. Please log in or start a trial to view this content.